“We have investigated the endocannabinoid system in the motor cortex of motor neuron disease (MND) patients.
CONCLUSION:
We have confirmed that CB
2 receptors are elevated in the motor cortex of MND patients associated with the reactive gliosis. This phenomenon is previous to neuronal losses. We also found CB
2 receptors in cortical and spinal motor neurons.
These observations support that targeting this receptor may serve for developing neuroprotective therapies in MNDs.”
https://www.ncbi.nlm.nih.gov/pubmed/29334787
http://www.tandfonline.com/doi/abs/10.1080/21678421.2018.1425454?journalCode=iafd20]]>